Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL)

Key Points

• Improved clinical outcomes are observed in younger patients with relapsed large B-cell lymphoma.
• Treatment with lisocabtagene maraleucel shows significant efficacy in achieving durable responses.
• Observational analysis of younger patients highlights the importance of tailored therapies for relapsed conditions.
• Clinical outcomes from this intervention may support further exploration in broader populations.